Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

miR-149-3p reverses CD8+ T-cell exhaustion by reducing inhibitory receptors and promoting cytokine secretion in breast cancer cells.

Zhang M, Gao D, Shi Y, Wang Y, Joshi R, Yu Q, Liu D, Alotaibi F, Zhang Y, Wang H, Li Q, Zhang ZX, Koropatnick J, Min W.

Open Biol. 2019 Oct 31;9(10):190061. doi: 10.1098/rsob.190061. Epub 2019 Oct 9.

2.

TdIF1: a putative oncogene in NSCLC tumor progression.

Zhang Y, Wang Z, Huang Y, Ying M, Wang Y, Xiong J, Liu Q, Cao F, Joshi R, Liu Y, Xu D, Zhang M, Yuan K, Zhou N, Koropatnick J, Min W.

Signal Transduct Target Ther. 2018 Oct 19;3:28. doi: 10.1038/s41392-018-0030-9. eCollection 2018.

3.

Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy.

Gameiro SF, Ghasemi F, Barrett JW, Koropatnick J, Nichols AC, Mymryk JS, Maleki Vareki S.

Oncoimmunology. 2018 Jul 30;7(10):e1498439. doi: 10.1080/2162402X.2018.1498439. eCollection 2018.

4.

Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines.

Maleki Vareki S, Salim KY, Danter WR, Koropatnick J.

PLoS One. 2018 Jan 24;13(1):e0191766. doi: 10.1371/journal.pone.0191766. eCollection 2018.

5.

Correction: COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo.

Salim KY, Vareki SM, Danter WR, San-Marina S, Koropatnick J.

Oncotarget. 2017 Sep 1;8(36):60724. doi: 10.18632/oncotarget.20600. eCollection 2017 Sep 1.

6.

Synergistic Antiproliferative Activity of the RAD51 Inhibitor IBR2 with Inhibitors of Receptor Tyrosine Kinases and Microtubule Protein.

Ferguson PJ, Vincent MD, Koropatnick J.

J Pharmacol Exp Ther. 2018 Jan;364(1):46-54. doi: 10.1124/jpet.117.241661. Epub 2017 Oct 23.

PMID:
29061656
7.

Voluntary running exercise protects against sepsis-induced early inflammatory and pro-coagulant responses in aged mice.

Tyml K, Swarbreck S, Pape C, Secor D, Koropatnick J, Feng Q, Veldhuizen RAW, Gill SE.

Crit Care. 2017 Aug 8;21(1):210. doi: 10.1186/s13054-017-1783-1.

8.

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.

Petrova PS, Viller NN, Wong M, Pang X, Lin GH, Dodge K, Chai V, Chen H, Lee V, House V, Vigo NT, Jin D, Mutukura T, Charbonneau M, Truong T, Viau S, Johnson LD, Linderoth E, Sievers EL, Maleki Vareki S, Figueredo R, Pampillo M, Koropatnick J, Trudel S, Mbong N, Jin L, Wang JC, Uger RA.

Clin Cancer Res. 2017 Feb 15;23(4):1068-1079. doi: 10.1158/1078-0432.CCR-16-1700. Epub 2016 Nov 17.

9.

From Solo in the Silo to Strategic Training Programs.

Koritzinsky M, Koch CA, Riley B, Beauchemin N, Johnston G, Johnston M, Koropatnick J, Loiselle CG, Maslowska M, McCormick C, Miller WH Jr, Mulligan L, Tsao MS.

CBE Life Sci Educ. 2016 Spring;15(1):le1. No abstract available.

10.

COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo.

Salim KY, Maleki Vareki S, Danter WR, Koropatnick J.

Oncotarget. 2016 Jul 5;7(27):41363-41379. doi: 10.18632/oncotarget.9133. Erratum in: Oncotarget. 2017 Sep 1;8(36):60724.

11.

Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.

Rytelewski M, Maleki Vareki S, Mangala LS, Romanow L, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Figueredo R, Ferguson PJ, Vincent M, Sood AK, Koropatnick JD.

Oncotarget. 2016 Apr 12;7(15):20825-39. doi: 10.18632/oncotarget.7883.

12.

IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells.

Maleki Vareki S, Chen D, Di Cresce C, Ferguson PJ, Figueredo R, Pampillo M, Rytelewski M, Vincent M, Min W, Zheng X, Koropatnick J.

PLoS One. 2015 Nov 18;10(11):e0143435. doi: 10.1371/journal.pone.0143435. eCollection 2015.

13.

Non-Covalently Functionalized of Single-Walled Carbon Nanotubes by DSPE-PEG-PEI for SiRNA Delivery.

Siu KS, Zhang Y, Zheng X, Koropatnick J, Min WP.

Methods Mol Biol. 2016;1364:151-63. doi: 10.1007/978-1-4939-3112-5_13.

PMID:
26472449
14.

Synergistic cytotoxicity against human tumor cell lines by oncolytic adenovirus dl1520 (ONYX-015) and melphalan.

Ferguson PJ, Sykelyk A, Figueredo R, Koropatnick J.

Tumori. 2016 Jan-Feb;102(1):31-9. doi: 10.5301/tj.5000438. Epub 2015 Sep 30.

PMID:
26429639
15.

siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine.

Di Cresce C, Figueredo R, Rytelewski M, Maleki Vareki S, Way C, Ferguson PJ, Vincent MD, Koropatnick J.

Oncotarget. 2015 Sep 8;6(26):22397-409.

16.

Evaluating the effectiveness of cancer drug sensitization in vitro and in vivo.

Rytelewski M, Buensuceso A, Leong HS, Deroo BJ, Chambers AF, Koropatnick J.

J Vis Exp. 2015 Feb 6;(96). doi: 10.3791/52388.

17.

Single-walled carbon nanotubes noncovalently functionalized with lipid modified polyethylenimine for siRNA delivery in vitro and in vivo.

Siu KS, Zheng X, Liu Y, Zhang Y, Zhang X, Chen D, Yuan K, Gillies ER, Koropatnick J, Min WP.

Bioconjug Chem. 2014 Oct 15;25(10):1744-51. doi: 10.1021/bc500280q. Epub 2014 Sep 23.

PMID:
25216445
18.

BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis.

Rytelewski M, Tong JG, Buensuceso A, Leong HS, Maleki Vareki S, Figueredo R, Di Cresce C, Wu SY, Herbrich SM, Baggerly KA, Romanow L, Shepherd T, Deroo BJ, Sood AK, Chambers AF, Vincent M, Ferguson PJ, Koropatnick J.

Mol Oncol. 2014 Dec;8(8):1429-40. doi: 10.1016/j.molonc.2014.05.017. Epub 2014 Jun 6.

19.

Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.

Wagner SC, Markosian B, Ajili N, Dolan BR, Kim AJ, Alexandrescu DT, Dasanu CA, Minev B, Koropatnick J, Marincola FM, Riordan NH.

J Transl Med. 2014 May 13;12:127. doi: 10.1186/1479-5876-12-127. Review.

20.

Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin.

Maleki Vareki S, Rytelewski M, Figueredo R, Chen D, Ferguson PJ, Vincent M, Min W, Zheng X, Koropatnick J.

Oncotarget. 2014 May 15;5(9):2778-91.

21.

Targeted siRNA silencing of indoleamine 2, 3-dioxygenase in antigen-presenting cells using mannose-conjugated liposomes: a novel strategy for treatment of melanoma.

Chen D, Koropatnick J, Jiang N, Zheng X, Zhang X, Wang H, Yuan K, Siu KS, Shunnar A, Way C, Min WP.

J Immunother. 2014 Feb-Mar;37(2):123-34. doi: 10.1097/CJI.0000000000000022.

PMID:
24509175
22.

Non-covalently functionalized single-walled carbon nanotube for topical siRNA delivery into melanoma.

Siu KS, Chen D, Zheng X, Zhang X, Johnston N, Liu Y, Yuan K, Koropatnick J, Gillies ER, Min WP.

Biomaterials. 2014 Mar;35(10):3435-42. doi: 10.1016/j.biomaterials.2013.12.079. Epub 2014 Jan 11.

PMID:
24424208
23.

Vaccinia virus outperforms a panel of other poxviruses as a potent oncolytic agent for the control of head and neck squamous cell carcinoma cell lines.

Nichols AC, Yoo J, Um S, Mundi N, Palma DA, Fung K, Macneil SD, Koropatnick J, Mymryk JS, Barrett JW.

Intervirology. 2014;57(1):17-22. doi: 10.1159/000353854. Epub 2013 Aug 13.

24.

The epidemic of human papillomavirus and oropharyngeal cancer in a Canadian population.

Nichols AC, Palma DA, Dhaliwal SS, Tan S, Theuer J, Chow W, Rajakumar C, Um S, Mundi N, Berk S, Zhou R, Basmaji J, Rizzo G, Franklin JH, Fung K, Kwan K, Wehrli B, Salvadori MI, Winquist E, Ernst S, Kuruvilla S, Read N, Venkatesan V, Todorovic B, Hammond JA, Koropatnick J, Mymryk JS, Yoo J, Barrett JW.

Curr Oncol. 2013 Aug;20(4):212-9. doi: 10.3747/co.20.1375.

25.

Metallothionein-I- and -II-deficient mice display increased susceptibility to cadmium-induced fetal growth restriction.

Selvaratnam J, Guan H, Koropatnick J, Yang K.

Am J Physiol Endocrinol Metab. 2013 Sep 15;305(6):E727-35. doi: 10.1152/ajpendo.00157.2013. Epub 2013 Jul 23.

26.

Imaging tumor growth non-invasively using expression of MagA or modified ferritin subunits to augment intracellular contrast for repetitive MRI.

Rohani R, Figueredo R, Bureau Y, Koropatnick J, Foster P, Thompson RT, Prato FS, Goldhawk DE.

Mol Imaging Biol. 2014 Feb;16(1):63-73. doi: 10.1007/s11307-013-0661-8.

PMID:
23836502
27.

High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer.

Nichols AC, Palma DA, Chow W, Tan S, Rajakumar C, Rizzo G, Fung K, Kwan K, Wehrli B, Winquist E, Koropatnick J, Mymryk JS, Yoo J, Barrett JW.

JAMA Otolaryngol Head Neck Surg. 2013 Jun;139(6):617-22. doi: 10.1001/jamaoto.2013.3210.

PMID:
23787421
28.

Does HPV type affect outcome in oropharyngeal cancer?

Nichols AC, Dhaliwal SS, Palma DA, Basmaji J, Chapeskie C, Dowthwaite S, Franklin JH, Fung K, Kwan K, Wehrli B, Howlett C, Siddiqui I, Salvadori MI, Winquist E, Ernst S, Kuruvilla S, Read N, Venkatesan V, Todorovic B, Hammond JA, Koropatnick J, Mymryk JS, Yoo J, Barrett JW.

J Otolaryngol Head Neck Surg. 2013 Feb 1;42:9. doi: 10.1186/1916-0216-42-9.

29.

A case report and genetic characterization of a massive acinic cell carcinoma of the parotid with delayed distant metastases.

Nichols AC, Chan-Seng-Yue M, Yoo J, Agrawal SK, Starmans MH, Waggott D, Harding NJ, Dowthwaite SA, Palma DA, Fung K, Wehrli B, Macneil SD, Lambin P, Winquist E, Koropatnick J, Mymryk JS, Boutros PC, Barrett JW.

Case Rep Oncol Med. 2013;2013:270362. doi: 10.1155/2013/270362. Epub 2013 Apr 3.

30.

Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined "Complementary Lethality".

Rytelewski M, Ferguson PJ, Maleki Vareki S, Figueredo R, Vincent M, Koropatnick J.

Mol Ther Nucleic Acids. 2013 Mar 12;2:e78. doi: 10.1038/mtna.2013.7.

31.

A Pilot Study Comparing HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas by Whole Exome Sequencing.

Nichols AC, Chan-Seng-Yue M, Yoo J, Xu W, Dhaliwal S, Basmaji J, Szeto CC, Dowthwaite S, Todorovic B, Starmans MH, Lambin P, Palma DA, Fung K, Franklin JH, Wehrli B, Kwan K, Koropatnick J, Mymryk JS, Boutros P, Barrett JW.

ISRN Oncol. 2012;2012:809370. doi: 10.5402/2012/809370. Epub 2012 Dec 12.

32.

The Effects of N-acetylcysteine on ifosfamide efficacy in a mouse xenograft model.

Hanly L, Figueredo R, Rieder MJ, Koropatnick J, Koren G.

Anticancer Res. 2012 Sep;32(9):3791-8.

PMID:
22993321
33.

Frequent mutations in TP53 and CDKN2A found by next-generation sequencing of head and neck cancer cell lines.

Nichols AC, Yoo J, Palma DA, Fung K, Franklin JH, Koropatnick J, Mymryk JS, Batada NN, Barrett JW.

Arch Otolaryngol Head Neck Surg. 2012 Aug;138(8):732-9. doi: 10.1001/archoto.2012.1558.

PMID:
22911296
34.

Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model.

Zheng X, Koropatnick J, Chen D, Velenosi T, Ling H, Zhang X, Jiang N, Navarro B, Ichim TE, Urquhart B, Min W.

Int J Cancer. 2013 Feb 15;132(4):967-77. doi: 10.1002/ijc.27710. Epub 2012 Jul 20.

35.

Ki-67 expression predicts radiotherapy failure in early glottic cancer.

Nichols AC, Whelan F, Basmaji J, Dhaliwal S, Dowthwaite S, Chapeskie C, Read N, Palma DA, Fung K, Venkatesan V, Hammond JA, Franklin JH, Siddiqui I, Wehrli B, Kwan K, Koropatnick J, Mymryk JS, Barrett JW, Yoo J.

J Otolaryngol Head Neck Surg. 2012 Apr;41(2):124-30.

PMID:
22569013
36.

Reduction of tumorigenicity by placental extracts.

Marleau AM, McDonald G, Koropatnick J, Chen CS, Koos D.

Anticancer Res. 2012 Apr;32(4):1153-61.

PMID:
22493344
37.

Detection of circulating tumor cells in advanced head and neck cancer using the CellSearch system.

Nichols AC, Lowes LE, Szeto CC, Basmaji J, Dhaliwal S, Chapeskie C, Todorovic B, Read N, Venkatesan V, Hammond A, Palma DA, Winquist E, Ernst S, Fung K, Franklin JH, Yoo J, Koropatnick J, Mymryk JS, Barrett JW, Allan AL.

Head Neck. 2012 Oct;34(10):1440-4. doi: 10.1002/hed.21941. Epub 2011 Nov 11.

PMID:
22076949
38.

Imaging of homeostatic, neoplastic, and injured tissues by HA-based probes.

Veiseh M, Breadner D, Ma J, Akentieva N, Savani RC, Harrison R, Mikilus D, Collis L, Gustafson S, Lee TY, Koropatnick J, Luyt LG, Bissell MJ, Turley EA.

Biomacromolecules. 2012 Jan 9;13(1):12-22. doi: 10.1021/bm201143c. Epub 2011 Dec 12.

39.

Combining small interfering RNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5-fluorodeoxyuridine and pemetrexed.

Di Cresce C, Figueredo R, Ferguson PJ, Vincent MD, Koropatnick J.

J Pharmacol Exp Ther. 2011 Sep;338(3):952-63. doi: 10.1124/jpet.111.183178. Epub 2011 Jun 14.

PMID:
21673071
40.

Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

Ichim TE, Minev B, Braciak T, Luna B, Hunninghake R, Mikirova NA, Jackson JA, Gonzalez MJ, Miranda-Massari JR, Alexandrescu DT, Dasanu CA, Bogin V, Ancans J, Stevens RB, Markosian B, Koropatnick J, Chen CS, Riordan NH.

J Transl Med. 2011 Mar 4;9:25. doi: 10.1186/1479-5876-9-25.

41.

Antisense treatment in human prostate cancer and melanoma.

Di Cresce C, Koropatnick J.

Curr Cancer Drug Targets. 2010 Sep;10(6):555-65. Review.

PMID:
20482488
42.

Magnetic resonance imaging of cells overexpressing MagA, an endogenous contrast agent for live cell imaging.

Goldhawk DE, Lemaire C, McCreary CR, McGirr R, Dhanvantari S, Thompson RT, Figueredo R, Koropatnick J, Foster P, Prato FS.

Mol Imaging. 2009 May-Jun;8(3):129-39.

PMID:
19723470
43.

Expression of functional metallothionein isoforms in papillary thyroid cancer.

Liu ZM, Hasselt CA, Song FZ, Vlantis AC, Cherian MG, Koropatnick J, Chen GG.

Mol Cell Endocrinol. 2009 Apr 10;302(1):92-8. doi: 10.1016/j.mce.2008.12.017. Epub 2009 Jan 20.

PMID:
19356627
44.

Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene.

Ferguson PJ, Brisson AR, Koropatnick J, Vincent MD.

Cancer Lett. 2009 Feb 18;274(2):279-89. doi: 10.1016/j.canlet.2008.09.021. Epub 2008 Nov 4.

PMID:
18986763
45.

Exosomes as a tumor immune escape mechanism: possible therapeutic implications.

Ichim TE, Zhong Z, Kaushal S, Zheng X, Ren X, Hao X, Joyce JA, Hanley HH, Riordan NH, Koropatnick J, Bogin V, Minev BR, Min WP, Tullis RH.

J Transl Med. 2008 Jul 22;6:37. doi: 10.1186/1479-5876-6-37.

46.

ODN 491, a novel antisense oligodeoxynucleotide that targets thymidylate synthase, exerts cell-specific effects in human tumor cell lines.

Jason TL, Figueredo R, Ferguson PJ, Vincent MD, Berg RW, Koropatnick J.

DNA Cell Biol. 2008 May;27(5):229-40. doi: 10.1089/dna.2007.0674.

PMID:
18358073
48.

Induction of functional MT1 and MT2 isoforms by calcium in anaplastic thyroid carcinoma cells.

Liu ZM, Chen GG, Shum CK, Vlantis AC, Cherian MG, Koropatnick J, van Hasselt CA.

FEBS Lett. 2007 May 29;581(13):2465-72. Epub 2007 Apr 30.

49.

Mouse monocytes (RAW CELLS) and the handling of cysteine and homocysteine S-conjugates of inorganic mercury and methylmercury.

Zalups RK, Koropatnick J, Joshee L.

J Toxicol Environ Health A. 2007 May 15;70(10):799-809.

PMID:
17454556
50.

Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines.

Pandyra AA, Berg R, Vincent M, Koropatnick J.

J Pharmacol Exp Ther. 2007 Jul;322(1):123-32. Epub 2007 Apr 23.

PMID:
17452420

Supplemental Content

Loading ...
Support Center